Life Sciences

Jubilant HollisterStier Announces New President and Upcoming Availability of Expanded Production Capacity for Sterile Injectables

Jubilant HollisterStier (JHS), a leading US-based pharmaceutical contract manufacturer of sterile fill/finish injectables, ampules, ophthalmics and sterile liquid products announces the appointment of Chris Preti as President. He brings more than 25 years of broad pharmaceutical industry experience to JHS.


Chris Preti has 25 years of varied pharmaceutical experience in research and development, marketing and sales, and operations, including positions of increasing responsibility at Glaxo SmithKline and HollisterStier Allergy, where he was most recently President. Chris holds a Bachelor of Science degree and Master of Science degree in Chemistry from Furman University and a Master of International Business Studies degree from the Darla Moore School of Business at the University of South Carolina. Chris also completed the program in Transformational Leadership for Executives at the Wharton School of the University of Pennsylvania.

As previously announced in May 2022, Jubilant HollisterStier’s expansion plan that is investing ~285 million (USD) to double its capacity for fill and finish of sterile injectables at its Spokane, Washington facility, is progressing well. The investment is part of the company’s cooperative agreement providing 149.6 million (USD) from the US Government to expand its critical vaccine manufacturing capacity in the US.

Chris Preti commented, “This is an exciting time to join Jubilant HollisterStier, as the company continues to expand its capacity to address growing industry demand for the high-quality services we provide. As a leading contract manufacturer of injectable pharmaceutical products and sterile fill/finish injectables, ampules, ophthalmics and sterile liquid products, we are acutely aware of the supply chain issues that continue to challenge manufacturers. With this expansion, we are well-positioned to address the contract manufacturing needs of major producers throughout North America. My decades in the Pharma industry taught me the critical role of manufacturing in achieving commercial success, and I am delighted to be heading up an industry leader committed to providing the highest quality comprehensive services in partnership with our customers.”